Cargando…
2718. Prevalence of Infections Following Anti-CD30 Targeted Chimeric Antigen Receptor T-cell Therapy for Relapsed and Refractory Lymphoma
BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed or refractory hematologic malignancies. Clinical trials have demonstrated anti-CD30 CAR T-cell efficacy in patients with CD30+ malignancies such as Hodgkin lymphoma, but little is known about post...
Autores principales: | Mohnasky, Michael C, Huggins, Jonathan, Messina, Julia A, Saha, Manish K, Saullo, Jennifer, Smith, Melody, Stromberg, Joseph, Walsh, Megan, Andermann, Tessa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677856/ http://dx.doi.org/10.1093/ofid/ofad500.2329 |
Ejemplares similares
-
2708. Infectious Complications Among CD19 Chimeric Antigen Receptor T-cell Recipients
por: Huggins, Jonathan, et al.
Publicado: (2023) -
Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients
por: Wang, D., et al.
Publicado: (2020) -
Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
por: Zhou, Jin, et al.
Publicado: (2022) -
Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
por: Wu, Jiaying, et al.
Publicado: (2022) -
Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma
por: Sang, Wei, et al.
Publicado: (2022)